Ashley N Tran1, Rishabh Sachdev1, Zachary P Fricker2, Michael Leber3, Toni Zahorian3, Bhavesh Shah3, David P Nunes2, Michelle T Long4. 1. Evans Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. 2. Section of Gastroenterology, Evans Department of Medicine, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street 7th Floor, Boston, MA, 02118, USA. 3. Clinical Pharmacy, Boston Medical Center, Boston, MA, USA. 4. Section of Gastroenterology, Evans Department of Medicine, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street 7th Floor, Boston, MA, 02118, USA. mtlong@bu.edu.
Abstract
BACKGROUND: Treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) regimens has resulted in high rates of sustained virologic response (SVR). Treatment of vulnerable populations may be improved by incorporating an on-site intensive specialty pharmacy (ON-ISP). AIMS: To describe outcomes of HCV treatment at a safety-net hospital and proportion of subjects achieving SVR for those using the ON-ISP compared to an off-site pharmacy (OFF-SP). METHODS: A retrospective cohort study of 219 subjects treated for HCV with DAA at Boston Medical Center was conducted. Subject characteristics, virologic response, and pharmacy services used were recorded. We used multivariable logistic regression to test the association between ON-ISP and SVR after adjusting for covariates. RESULTS: SVR occurred in 71% of subjects by intention-to-treat (73% among ON-ISP users vs 57% among OFF-SP users) and 95% completing treatment per-protocol (96% among ON-ISP users vs 87% among OFF-SP users). Adjustment for age, sex, ethnicity, insurance, fibrosis, prior treatment, and MELD revealed an increased likelihood of SVR among users of ON-ISP: OR 6.0 (95% CI 1.18-31.0). No significant difference in treatment delay or adverse events was seen among users of either pharmacy type. CONCLUSIONS: HCV treatment with DAA was well tolerated, but the rate of SVR was low (71%) compared to trials. This was due to loss to follow-up, as the per-protocol rate of SVR was much higher (95%). Use of ON-ISP was associated with an increase in SVR and may be valuable for improving care for vulnerable populations.
BACKGROUND: Treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) regimens has resulted in high rates of sustained virologic response (SVR). Treatment of vulnerable populations may be improved by incorporating an on-site intensive specialty pharmacy (ON-ISP). AIMS: To describe outcomes of HCV treatment at a safety-net hospital and proportion of subjects achieving SVR for those using the ON-ISP compared to an off-site pharmacy (OFF-SP). METHODS: A retrospective cohort study of 219 subjects treated for HCV with DAA at Boston Medical Center was conducted. Subject characteristics, virologic response, and pharmacy services used were recorded. We used multivariable logistic regression to test the association between ON-ISP and SVR after adjusting for covariates. RESULTS: SVR occurred in 71% of subjects by intention-to-treat (73% among ON-ISP users vs 57% among OFF-SP users) and 95% completing treatment per-protocol (96% among ON-ISP users vs 87% among OFF-SP users). Adjustment for age, sex, ethnicity, insurance, fibrosis, prior treatment, and MELD revealed an increased likelihood of SVR among users of ON-ISP: OR 6.0 (95% CI 1.18-31.0). No significant difference in treatment delay or adverse events was seen among users of either pharmacy type. CONCLUSIONS:HCV treatment with DAA was well tolerated, but the rate of SVR was low (71%) compared to trials. This was due to loss to follow-up, as the per-protocol rate of SVR was much higher (95%). Use of ON-ISP was associated with an increase in SVR and may be valuable for improving care for vulnerable populations.
Authors: E B Tapper; B R Bacon; M P Curry; D T Dieterich; S L Flamm; L E Guest; K V Kowdley; Y Lee; N C Tsai; Z M Younossi; N H Afdhal Journal: J Viral Hepat Date: 2016-10-11 Impact factor: 3.728
Authors: H Wedemeyer; A Craxí; E Zuckerman; D Dieterich; R Flisiak; S K Roberts; A Pangerl; Z Zhang; M Martinez; Y Bao; J-L Calleja Journal: J Viral Hepat Date: 2017-07-03 Impact factor: 3.728
Authors: R J Wong; M T Nguyen; H N Trinh; A Huynh; M T Ly; H A Nguyen; K K Nguyen; J Yang; R T Garcia; B Levitt; E da Silveira; R G Gish Journal: J Viral Hepat Date: 2016-09-27 Impact factor: 3.728
Authors: Zobair M Younossi; Haesuk Park; Staurt C Gordon; John R Ferguson; Aijaz Ahmed; Douglas Dieterich; Sammy Saab Journal: Am J Manag Care Date: 2016-05 Impact factor: 2.229
Authors: George N Ioannou; Lauren A Beste; Michael F Chang; Pamela K Green; Elliott Lowy; Judith I Tsui; Feng Su; Kristin Berry Journal: Gastroenterology Date: 2016-06-04 Impact factor: 22.682
Authors: Esther Chamorro-de-Vega; Alvaro Gimenez-Manzorro; Carmen Guadalupe Rodriguez-Gonzalez; Vicente Escudero-Vilaplana; Roberto Collado Borrell; Sara Ibañez-Garcia; Elena Lallana Sainz; Elena Lobato Matilla; Ana Lorenzo-Pinto; Silvia Manrique-Rodriguez; Cecilia M Fernandez-Llamazares; MariaBelen Marzal-Alfaro; Almudena Ribed; Rosa Maria Romero Jimenez; Camino Sarobe Gonzalez; Ana Herranz; Maria Sanjurjo Journal: Ann Pharmacother Date: 2016-07-20 Impact factor: 3.154
Authors: Paul Feuerstadt; Ari L Bunim; Heriberto Garcia; Jordan J Karlitz; Hatef Massoumi; Amar J Thosani; Andrew Pellecchia; Allan W Wolkoff; Paul J Gaglio; John F Reinus Journal: Hepatology Date: 2010-04 Impact factor: 17.425
Authors: Jesse Powell; Margaret Ricco; Jessica Naugle; Catherine Magee; Hayat Hassan; Carmen Masson; Grace Braimoh; Barry Zevin; Mandana Khalili Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 3.835